Quest Diagnostics Incorporated , the nation's leading provider of diagnostic testing, information and services, announced today that it has signed a multi-year contract extension with CIGNA HealthCare and will remain a participating provider in all markets for all products. Quest Diagnostics is the largest provider of laboratory services to CIGNA HealthCare, providing its members and providers with the nation's broadest access to laboratory services. Financial terms were not disclosed.

"We are very pleased to continue to serve CIGNA HealthCare's members and providers across the country," said Surya N. Mohapatra, Ph.D., Chairman and Chief Executive Officer, Quest Diagnostics. "CIGNA HealthCare continues to offer its providers choice in laboratory services, and we are delighted to compete on the basis of the quality and service we provide."

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: http://www.questdiagnostics.com/

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors described in the Quest Diagnostics Incorporated 2006 Form 10-K and subsequent SEC filings.

First Call Analyst:
FCMN Contact:

SOURCE: Quest Diagnostics

CONTACT: Investors, Laure Park, +1-201-393-5030, Media, Nancy
Fitzsimmons, +1-201-393-5700, both of Quest Diagnostics

Web site: http://www.questdiagnostics.com/